INBX Earnings & Financial Statements
Inhibrx Biosciences, Inc.
$85.26
-$1.82(-2.09%)
38
Overall
40
Value
30
Tech
44
Quality
Market Cap
$1.25B
Volume
246.06K
52W Range
$46.01 - $155.29
Target Price
$266.67
INBX earnings and financial statements: Inhibrx Biosciences, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
INBX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1.30M | $200.0K | $1.80M | $2.18M | $7.13M |
| Operating income | -$135.03M | -$331.45M | -$218.64M | -$129.12M | -$76.56M |
| EBITDA | -$122.94M | $1.71B | -$205.53M | -$125.82M | -$75.36M |
| Net income | -$140.06M | $1.69B | -$240.20M | -$145.23M | -$81.77M |
| EPS (diluted) | $-9.04 | $112.62 | $-20.48 | $-3.62 | $-2.15 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $146.48M | $180.77M | $307.89M | $290.88M | $150.45M |
| Total liabilities | $138.49M | $47.18M | $264.39M | $232.82M | $98.07M |
| Shareholders’ equity | $7.99M | $133.58M | $43.50M | $58.06M | $52.38M |
| Cash and equivalents | $124.22M | $152.60M | $277.92M | $273.87M | $131.30M |
| Long-term debt | $104.69M | $6.45M | $208.08M | $205.24M | $75.50M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$129.79M | -$194.41M | -$193.31M | -$115.30M | -$80.32M |
| Capital expenditure | -$28.0K | -$2.60M | - | -$686.0K | -$809.0K |
| Free cash flow | -$129.82M | -$197.01M | -$197.90M | -$115.99M | -$81.13M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | INBX | $85.26 | -2.1% | 246.06K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Inhibrx Biosciences, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW